Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001181431-14-030574
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-08-29 17:41:57
Reporting Period:
2014-08-27
Filing Date:
2014-08-29
Accepted Time:
2014-08-29 17:41:57
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1061027 Sunesis Pharmaceuticals Inc SNSS Pharmaceutical Preparations (2834) 943295878
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1270521 Kittu Krishna Kolluri 1954 Greenspring Drive
Suite 600
Timonium MD 21093
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2014-08-27 108,300 $8.17 4,817,733 No 4 S Indirect See Note 2
Common Stock Disposition 2014-08-28 146,800 $7.87 4,670,933 No 4 S Indirect See Note 2
Common Stock Disposition 2014-08-29 11,600 $7.51 4,659,333 No 4 S Indirect See Note 2
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Note 2
No 4 S Indirect See Note 2
No 4 S Indirect See Note 2
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.05 to $8.275, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.
  2. The Reporting Person is a manager of NEA 12 GP, LLC, which is the sole general partner of NEA Partners 12, Limited Partnership ("NEA Partners 12"). NEA Partners 12 is the sole general partner of New Enterprise Associates 12, Limited Partnership, ("NEA 12"). NEA 12 is the sole member of Growth Equity Opportunities Fund, LLC ("GEO"), the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares of the Issuer held by GEO in which the Reporting Person has no pecuniary interest.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.76 to $8.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.50 to $7.545, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.